symbol: DSCO exchange: NASDAQ industry: drugs homepage: www.discoverylabs.com email: investor relations To receive notification when financials or news releases are updated, enter your email address below. REPORTS EARNINGS Company reported for the second quarter ended 6/30/02 a net loss of $(4,287,000) or $(0.16) per share on revenues of $783,000 vs. a net loss of $(2,355,000) or $(0.11) per share on revenues of $262,000 for the same period last year. click here for more ......

Discovery Laboratories, Inc. is a Doylestown, Pennsylvania based bio-pharmaceutical company. Its mission is to develop and commercialize medically novel therapeutics for critical care. Presently, Discovery is focusing on diseases of the lung, with its initial emphasis on the treatment of neonatal indications, such as meconium aspiration syndrome in full-term infants and respiratory distress syndrome in premature infants. Discovery is also developing proprietary pharmaceuticals to treat acute respiratory distress syndrome/acute lung injury and cystic fibrosis.

November of 1996, Discovery completed a private financing of over $22 million. In November of 1997, Discovery merged with Ansan Pharmaceuticals, a publicly traded, development stage pharmaceutical company. On June 16, 1998, Discovery merged with its major owned subsidiary, Acute Therapeutics, Inc. Discovery’s shares are traded on the Nasdaq under the symbols: DSCO (common stock) and DSCOU (units). Discovery is actively seeking to in-license novel clinical candidates and technologies.